IRIS
CAVALLI, GIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 546
NA - Nord America 479
AS - Asia 73
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 2
Totale 1.102
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 475
SE - Svezia 390
IT - Italia 84
CN - Cina 48
FI - Finlandia 23
DE - Germania 17
IE - Irlanda 16
IN - India 9
SG - Singapore 7
GB - Regno Unito 6
CA - Canada 4
NL - Olanda 4
PH - Filippine 4
RU - Federazione Russa 4
IR - Iran 3
EU - Europa 2
TN - Tunisia 2
ID - Indonesia 1
IQ - Iraq 1
ME - Montenegro 1
UA - Ucraina 1
Totale 1.102
Salva come PNG Salva come JPEG
Città #
Lawrence 107
Princeton 107
New York 51
Shanghai 47
Ashburn 38
Helsinki 22
Dublin 16
Milan 11
Seattle 9
Rome 6
Los Angeles 5
Pune 5
Saint Louis 5
Verona 5
Bologna 4
Mestrino 4
Quezon City 4
Angera 3
Gallarate 3
London 3
Vittoria 3
Arnsberg 2
Balasore 2
Castel Mella 2
Hyderabad 2
Padova 2
Segrate 2
Singapore 2
Torre Del Greco 2
York 2
Amsterdam 1
Ancona 1
Beijing 1
Borås 1
Capaccio 1
Chandler 1
Chelyabinsk 1
Fiumefreddo Di Sicilia 1
Gorodishche 1
Gunzenhausen 1
Hanover 1
Issogne 1
Jakarta 1
Lainate 1
Lappeenranta 1
Maidenhead 1
Moscow 1
Nizhniy Novgorod 1
Paliano 1
Parma 1
Perugia 1
Podgorica 1
Reeuwijk 1
San Diego 1
San Sperate 1
Santa Clara 1
Secaucus 1
Sezze 1
Toronto 1
Torre Boldone 1
Washington 1
Wilmington 1
Totale 508
Salva come PNG Salva come JPEG
Nome #
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 41
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 30
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli 28
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 26
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 25
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study 22
Testosterone in males with COVID-19: A twelve-month cohort study 21
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 21
A bitter effect: thrombocytopenia induced by a quinidine-containing beverage 20
Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease 20
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 20
Anakinra for patients with COVID-19: an updated systematic review and meta-analysis 19
Assessing the role of pentraxin-3 in Takayasu's arteritis. Comment on: Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Alibaz-Oner F. et al 19
Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis 19
Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series 18
A Novel Histiocytosis With Synovial and Skin Involvement 18
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 17
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 17
A virus-free cellular model recapitulates several features of severe COVID-19 17
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 16
Autophagy and Protein Secretion 16
Anakinra for patients with COVID-19 – Authors' reply 16
Current treatment options and safety considerations when treating adult-onset Still’s disease 16
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease 16
Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it? 15
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use 15
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 15
Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies 15
Immunosuppressive strategies in invasively ventilated ARDS COVID-19 patients 15
Advances in potential targeted therapies for Erdheim-Chester disease 14
Aortic thrombosis secondary to clopidogrel-related thrombotic thrombocytopenic purpura 14
An enlightening scan 14
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 13
BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. 13
Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset still's disease: A multicentre retrospective observational study 13
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 13
Testosterone in males with COVID-19: A 7-month cohort study 13
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation 12
Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series 12
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease 12
QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk 12
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 12
Anakinra therapy for non-cancer inflammatory diseases 12
Anakinra for COVID-19: how to interpret elevations in serum liver enzymes 12
ROLE OF TRAINED IMMUNITY AND IMMUNOMETABOLISM IN THE PATHOGENESIS OF ERDHEIM-CHESTER DISEASE 11
Treating Experimental Arthritis with the Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation 11
The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease 11
Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis 11
Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients 11
Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis 11
CARDIAC CINE MRI IN ERDHEIM-CHESTER DISEASE: DATA FROM A LARGE ITALIAN COHORT 10
Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance 10
3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target 10
Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition 10
Myocarditis: An Interleukin-1-Mediated Disease? 10
Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease (Arthritis Research and Therapy (2019) 21 (54) DOI: 10.1186/s13075-019-1843-9) 10
Suppression of inflammation and acquired immunity by IL-37 10
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 10
Treating Life-Threatening Myocarditis by Blocking Interleukin-1 10
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey 9
Methotrexate in refractory bilateral juvenile temporal arteritis: Report of a case 9
Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis: The Role of Cardiac Magnetic Resonance 9
Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease 9
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 9
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies 9
Erdheim-Chester disease: An in vivo human model of Mϕ activation at the crossroad between chronic inflammation and cancer 9
Large Vessel Vasculitis Affecting the Aorta and Its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature 9
Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement 9
Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients 9
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis 9
Erdheim-Chester disease. 8
Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab 8
Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease 8
Treating Pulmonary Silicosis by Blocking Interleukin 1 8
Tocilizumab in patients with multisystem Erdheim–Chester disease 8
Priorities of biomedical research 8
Hypertrophic cardiomyopathy secondary to hepatitis C virus-related vasculitis 8
Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis 8
Letter by Campochiaro et al regarding article, “Clinical features, management, and outcomes of immune checkpoint inhibitor–Related cardiotoxicity” 8
Autoimmune vitiligo is associated with gain-offunction by a transcriptional regulator that elevates expression of HLA-A∗02:01 in vivo 8
Charcot's arthropathy of the hip 8
Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout 8
The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity 8
The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. 7
TUMOUR NECROSIS FACTOR-ALPHA AS A MASTER REGULATOR OF INFLAMMATION IN ERDHEIM-CHESTER DISEASE: RATIONALE FOR THE SUCCESSFUL TREATMENT OF TWO PATIENTS WITH INFLIXIMAB 7
Charcot's arthropathy of the spine 7
Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes 7
CEREBROSPINAL-FLUID S-ADENOSYLMETHIONINE (SAME) AND GLUTATHIONE CONCENTRATIONS IN HIV-INFECTION - EFFECT OF PARENTERAL TREATMENT WITH SAME 7
Corrigendum: Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation [Rheumatology, 55, (2016), (2220-2229)] doi:10.1093/rheumatology/kew325 7
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial 7
Cutaneous vasculitis following COVID-19 vaccination 7
Efficacy and safety of biological agents in adult-onset Still's disease 6
Efficacy and Safety Of Biologic Agents In Adult-Onset Still's Disease: A Long-Term Follow-Up Of 19 Patients At a Single Referral Center 6
EFFICACY OF ORAL TACROLIMUS IN TWO PATIENTS WITH SCLERITIS AND RELAPSING POLYCHONDRITIS 6
Diagnosing Erdheim-Chester disease 6
Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease 6
Prevalence of Takayasu arteritis in young women with acute ischemic heart disease 6
Impact of rare and common genetic variation in the interleukin-1 pathway on human cytokine responses 6
Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply 6
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 6
Totale 1.233
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.144
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.144
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202060 4 0 0 0 0 0 0 0 0 0 55 1
2020/202150 2 0 5 5 0 12 9 3 2 4 6 2
2021/2022128 1 0 32 31 11 11 4 2 21 3 8 4
2022/2023678 240 157 53 5 12 81 27 52 33 2 8 8
2023/2024369 17 40 60 43 48 72 23 52 5 8 1 0
Totale 1.308